Transgene

• Placement of 13.9m new shares at a subscription price of €2.45 per share, generating gross proceeds of approximately €34.1m
• Transgene intents to use circa €25m of the net proceeds to finalise clinical studies, circa €4m to launch the clinical development of new oncolytic viruses based on the Invir.IOTM platform, and the remainder of the proceeds to finance R&D and operational costs
• Existing shareholders Institut Mérieux and SITAM Belgium participated in the capital increase for a total amount of €25m and €1.67m , respectively. Several specialised healthcare investors, including Invus, also participated in the transaction 
• This transaction marks the third transaction in which Kempen & Co assisted the Company following a capital increase in 2016 and 2019, underpinning our ambition to be a long-term partner for our clients
• In 2021, year to date, Kempen & Co has already executed 17 transactions for European life sciences companies

Transgene is a French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilise viral vector technology with the goal of indirectly or directly killing cancerous cells. The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualised therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Global Coordinator & Joint Bookrunner in the SEK 141m Capital Increase by Immunicum
• Lead Manager in Molecular Partners’ USD 63.8m Initial Public Offering on Nasdaq
• Joint Bookrunner in the SEK 301m Capital Increase by Q-linea
• Co-Manager in the USD 176m Nasdaq Initial Public Offering by Achilles Therapeutics 
• Joint Bookrunner in the €30m Capital Increase by GenSight Biologics
• Lead Manager in the USD 101m Nasdaq Initial Public Offering by LAVA Therapeutics
• Joint Bookrunner in the USD 120m Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
• Joint Bookrunner in the SEK 1.1 billion Capital Increase by Oncopeptides
• Joint Global Coordinator and Joint Bookrunner in the SEK 962m Capital Increase by BioInvent
• Joint Global Coordinator and Joint Bookrunner in the €22.5m Capital Increase by Sequana Medical
• Co-Manager in the USD 115m US Public Offering by Y-mAbs Therapeutics
• Co-Manager in the USD 115m US Public Offering by Autolus Therapeutics
• Co-Manager in the USD 190m Nasdaq Initial Public Offering by Pharvaris
• Bookrunner in the USD 518m US Public Offering by CureVac
• Lead Manager in the USD 120m US Public Offering by Merus 
• Financial Adviser to DCprime in its merger with Immunicum 
• Joint Bookrunner in the SEK 564m Capital Increase by Cantargia
• Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2m
• Placement Agent in Investinor’s Secondary Sell-Down of c. 4m shares in Calliditas Therapeutics
• Lead Manager in the USD 95.1m Nasdaq Initial Public Offering by Galecto
• Joint Bookrunner in the €31m Capital Increase by Sensorion
• Bookrunner in the USD 245m Nasdaq Initial Public Offering by CureVac
• Co-Manager in the USD 49m US Public Offering by Centogene
• Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
• Joint Bookrunner in the CHF 80.2m Capital Increase by Molecular Partners
• Co-Manager in the USD 690m US Public Offering by Ascendis Pharma
• Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp, thereby becoming a Nasdaq listed company and securing USD 253m
• Joint Global Coordinator and Joint Bookrunner in the €61.8m Initial Public Offering by Hyloris Pharmaceuticals